Director/PDMR Shareholding
22/05/2026 14:17
RNS Number : 5125F Oxford Biomedica PLC 22 May 2026 PDMR Dealing Oxford, UK - 22 May 2026: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Natalie Walter, Chief Legal Officer and Group Company Secretary has exercised 3,816 Deferred Bonus Plan (DBP) options at an exercise price of £nil per share on 22 May 2026 and disposed of 3,816 ordinary shares at an average price of £6.145 per share on 22 May 2026. In addition, Lisa Doman, Chief People Officer, exercised 3,564 Deferred Bonus Plan (DBP) options at an exercise price of £nil per share and sold 3,564 ordinary shares at an average price of £6.145 per share on 22 May 2026. The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.
| 1. | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Natalie Walter | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief Legal Officer and Group Company Secretary | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Date of the transaction | 22-May-2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Exercise of 3,816 DBP options | ||||
| e) | Place of the transaction | Outside the trading venue | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,816 £0.00 £0.00 | ||||
| 1. | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Natalie Walter | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief Legal Officer and Group Company Secretary | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Date of the transaction | 22-May-2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Sale of 3,816 ordinary shares | ||||
| e) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,816 £6.145 £23,449.32 | ||||
| 1. | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Lisa Doman | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief People Officer | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Date of the transaction | 22 May 2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Exercise of DBP options | ||||
| e) | Place of the transaction | Outside the trading venue | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,564 £nil £nil | ||||
| 1. | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||||
| b) | Name of natural person | Lisa Doman | ||||||
| c) | Legal person | |||||||
| 2. | Reason for the notification | |||||||
| a) | Position/status | Chief People Officer | ||||||
| b) | Initial notification/ amendment | Initial Notification | ||||||
| 3. | Details of the Issuer | |||||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Date of the transaction | 22 May 2026 | ||||||
| b) | Description of the financial instrument | Share | ||||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||||
| d) | Nature of the transaction | Sale of 3,564 ordinary shares | ||||||
| e) | Place of the transaction | Outside the trading venue | ||||||
| f) | Currency | GBP - British pound | ||||||
| g) | Price(s) and volumes(s) |
| ||||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,564 £6.145 £21,900.78 | ||||||